Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience
{{output}}
Aim: The use of venetoclax in combination with hypomethylating agents (HMAs) has become a standard treatment approach for both newly diagnosed and relapsed/refractory (R/R) AML patients who are ineligible for intensive chemothera... ...
